LTRN (Lantern Pharma) Interest Coverage : N/A (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Lantern Pharma's Operating Income for the three months ended in Mar. 2025 was $-4.77 Mil. Lantern Pharma's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Lantern Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Lantern Pharma's Interest Coverage or its related term are showing as below:

LTRN's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lantern Pharma Interest Coverage Historical Data

The historical data trend for Lantern Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lantern Pharma Interest Coverage Chart

Lantern Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

Get a 7-Day Free Trial

N/A

No Debt

N/A

Lantern Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Coverage	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Lantern Pharma's Interest Coverage

For the Biotechnology subindustry, Lantern Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantern Pharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lantern Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Lantern Pharma's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Lantern Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lantern Pharma's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Lantern Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-22.22 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.05 Mil.

GuruFocus does not calculate Lantern Pharma's interest coverage with the available data.

Lantern Pharma's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Lantern Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-4.77 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.03 Mil.

GuruFocus does not calculate Lantern Pharma's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

Lantern Pharma (NAS:LTRN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Lantern Pharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantern Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201

Website

https://www.lanternpharma.com

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Executives

Leslie W. Kreis	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l.	10 percent owner	40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini	director	1223 FOXGLOVE LANE, WEST CHESTER PA 19380